Trial Profile
A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Nelarabine (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Large granular lymphocytic leukaemia; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sezary syndrome; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 29 Nov 2022 Results assessing the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies published in the Cancer
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.